Jun 2026 (Q2 FY26) — Aug 4, 2026
SOPHiA GENETICS Q2 FY26 — Strong US Growth and Landmark CDx Deals
Read the full callSOPHiA GENETICS (SOPH) earnings
- Jun 2026 (Q2 FY26)
- Dec 2025
SOPHiA GENETICS earnings: last reported Tue, 4 Aug 2026, for the quarter ended Jun 2026.
Price
$7.29 +3.26% · +$0.23
Performance +72.3% 1Y
1Y: $4.23 on 14 Oct 2025 → $7.29. High $8.92 (27 Aug 2026), low $3.89 (20 Nov 2025).
- Previous close
- $7.06
- 52-week range
- $3.89 – $8.92
- One year
- +69.93%
Overview
- Symbol
- SOPH
- Sector
- Information Technology
- Industry
- Services-Computer Processing & Data Preparation
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
SOPHiA GENETICS earnings calls (SOPH)
Financials
What the filings say
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total liabilities | — | 32 | 45 | 44 | 55 | 59 | 116 |
| Fixed assets | — | 2 | 5 | 7 | 7 | 5 | 6 |
| Total assets | — | 132 | 320 | 244 | 206 | 155 | 163 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -32 | -32 | -58 | -70 | -53 | -45 | -36 |
| Cash from investing | -3 | -24 | -57 | 42 | 13 | -5 | -9 |
| Cash from financing | -1 | 107 | 238 | -2 | -3 | 10 | 30 |
| Capital expenditure | -1 | -0 | -3 | -4 | -1 | -0 | -1 |
| Free cash flow | -33 | -32 | -61 | -74 | -55 | -45 | -36 |
Insider filings
172 filings between Mar 19, 2026 and Oct 13, 2026.
Open market
decisions to buy or sellPurchases
$99.0K
1 purchase by 1 insider
Sales
$5.18M
150 sales by 10 insiders
91% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 14
- Award — granted as compensation
- 7
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Camblong Jurgi | — | $2.73M | Oct 12, 2026 |
| Xu Zhenyu | — | $814.1K | Oct 13, 2026 |
| Menu Philippe | — | $538.9K | Oct 12, 2026 |
| Verma Abhimanyu | — | $283.1K | Oct 5, 2026 |
| Muken Ross | — | $249.7K | Oct 5, 2026 |
| Valente Manuela | — | $183.6K | Oct 5, 2026 |
| Van Well Daan | — | $166.5K | Oct 5, 2026 |
| CARDOZA GEORGE | $99.0K | $66.4K | Oct 5, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 13, 2026 | Xu Zhenyu Chief Scientific Officer | Sale 10b5-1 plan | 4,000 | $28.7K |
| Oct 12, 2026 | Menu Philippe Chief Medical Officer | Sale 10b5-1 plan | 5,000 | $36.3K |
| Oct 12, 2026 | Camblong Jurgi Executive Chairman | Sale 10b5-1 plan | 8,500 | $61.7K |
| Oct 5, 2026 | Xu Zhenyu Chief Scientific Officer | Sale 10b5-1 plan | 7,394 | $60.1K |
| Oct 5, 2026 | Valente Manuela Chief People Officer | Sale 10b5-1 plan | 4,240 | $34.5K |
| Oct 5, 2026 | Camblong Jurgi Executive Chairman | Sale 10b5-1 plan | 40,172 | $326.5K |
| Oct 5, 2026 | Verma Abhimanyu Chief Technology Officer | Sale 10b5-1 plan | 5,284 | $42.9K |
| Oct 5, 2026 | CARDOZA GEORGE Chief Financial Officer | Sale 10b5-1 plan | 1,592 | $12.9K |
| Oct 5, 2026 | Menu Philippe Chief Medical Officer | Sale 10b5-1 plan | 7,394 | $60.1K |
| Oct 5, 2026 | Puylaert Kevin Chief Sales Officer | Sale | 185 | $1.5K |
| Oct 5, 2026 | Van Well Daan Chief Legal Officer | Sale 10b5-1 plan | 6,168 | $50.1K |
| Oct 5, 2026 | Puylaert Kevin Chief Sales Officer | Sale | 31 | $246 |
| Oct 5, 2026 | Muken Ross Chief Executive Officer | Sale 10b5-1 plan | 9,838 | $80.0K |
| Sep 21, 2026 | CARDOZA GEORGE Chief Financial Officer | Sale 10b5-1 plan | 774 | $6.4K |
| Sep 21, 2026 | Muken Ross Chief Executive Officer | Sale 10b5-1 plan | 422 | $3.5K |
| Sep 14, 2026 | Xu Zhenyu Chief Scientific Officer | Sale 10b5-1 plan | 4,000 | $31.5K |
| Sep 14, 2026 | Menu Philippe Chief Medical Officer | Sale | 5,000 | $39.4K |
| Sep 11, 2026 | Van Well Daan Chief Legal Officer | Sale 10b5-1 plan | 6,168 | $47.1K |
| Sep 10, 2026 | Camblong Jurgi Executive Chairman | Sale 10b5-1 plan | 8,500 | $65.1K |
| Sep 8, 2026 | HIBBS KATHY L Director | Sale 10b5-1 plan | 6,250 | $50.8K |
| Aug 27, 2026 | Xu Zhenyu Chief Scientific Officer | Sale 10b5-1 plan | 10,000 | $89.1K |
| Aug 25, 2026 | Menu Philippe Chief Medical Officer | Sale 10b5-1 plan | 5,000 | $43.4K |
| Aug 25, 2026 | HIBBS KATHY L Director | Sale 10b5-1 plan | 6,250 | $54.2K |
| Aug 24, 2026 | Verma Abhimanyu Chief Technology Officer | Sale 10b5-1 plan | 5,000 | $44.0K |
| Aug 21, 2026 | Xu Zhenyu Chief Scientific Officer | Sale 10b5-1 plan | 5,408 | $45.4K |
| Aug 20, 2026 | Xu Zhenyu Chief Scientific Officer | Sale 10b5-1 plan | 4,592 | $38.6K |
| Aug 19, 2026 | Verma Abhimanyu Chief Technology Officer | Sale 10b5-1 plan | 5,000 | $41.0K |
| Aug 19, 2026 | Valente Manuela Chief People Officer | Option exercise 10b5-1 plan | 10,000 | $32.0K |
| Aug 19, 2026 | Xu Zhenyu Chief Scientific Officer | Sale 10b5-1 plan | 10,000 | $79.4K |
| Aug 19, 2026 | Valente Manuela Chief People Officer | Sale 10b5-1 plan | 10,000 | $79.4K |
| Aug 13, 2026 | Xu Zhenyu Chief Scientific Officer | Sale 10b5-1 plan | 4,000 | $30.1K |
| Aug 12, 2026 | Menu Philippe Chief Medical Officer | Sale 10b5-1 plan | 5,000 | $37.6K |
| Aug 10, 2026 | Camblong Jurgi Executive Chairman | Sale 10b5-1 plan | 8,500 | $64.7K |
| Aug 7, 2026 | Verma Abhimanyu Chief Technology Officer | Sale 10b5-1 plan | 5,000 | $38.0K |
| Aug 7, 2026 | Camblong Jurgi Executive Chairman | Sale 10b5-1 plan | 20,000 | $144.5K |
| Aug 7, 2026 | Xu Zhenyu Chief Scientific Officer | Sale 10b5-1 plan | 10,000 | $74.8K |
| Aug 7, 2026 | Xu Zhenyu Chief Scientific Officer | Sale 10b5-1 plan | 7,000 | $49.2K |
| Aug 7, 2026 | Xu Zhenyu Chief Scientific Officer | Option exercise 10b5-1 plan | 7,000 | $23.0K |
| Aug 5, 2026 | Xu Zhenyu Chief Scientific Officer | Option exercise 10b5-1 plan | 3,000 | $9.8K |
| Aug 5, 2026 | Xu Zhenyu Chief Scientific Officer | Sale 10b5-1 plan | 3,000 | $21.0K |
| Aug 4, 2026 | Verma Abhimanyu Chief Technology Officer | Sale 10b5-1 plan | 5,000 | $34.8K |
| Aug 4, 2026 | Camblong Jurgi Executive Chairman | Sale 10b5-1 plan | 20,000 | $138.4K |
| Aug 4, 2026 | Xu Zhenyu Chief Scientific Officer | Sale 10b5-1 plan | 10,000 | $69.2K |
| Jul 27, 2026 | Menu Philippe Chief Medical Officer | Sale 10b5-1 plan | 5,000 | $28.3K |
| Jul 21, 2026 | Camblong Jurgi Executive Chairman | Sale 10b5-1 plan | 20,000 | $132.7K |
| Jul 20, 2026 | Camblong Jurgi Executive Chairman | Sale 10b5-1 plan | 19,800 | $125.2K |
| Jul 20, 2026 | Camblong Jurgi Executive Chairman | Option exercise 10b5-1 plan | 4,581 | $14.5K |
| Jul 20, 2026 | Camblong Jurgi Executive Chairman | Sale 10b5-1 plan | 4,581 | $28.2K |
| Jul 13, 2026 | Menu Philippe Chief Medical Officer | Sale 10b5-1 plan | 5,000 | $28.5K |
| Jul 13, 2026 | Xu Zhenyu Chief Scientific Officer | Sale 10b5-1 plan | 4,000 | $22.8K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for SOPHiA GENETICS SA
Free account. Everything above stays public.
Write why you follow SOPHiA GENETICS SA and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading